What is the clinical efficacy of Odevixibat in actual treatment?

The efficacy of Odevixibat in the treatment of progressive familial intrahepatic cholestasis (PFIC) has been confirmed in multiple international clinical studies. As the first approved inhibitor of IBAT (bile salt transporter), orvixibat reduces the intestinal reabsorption of bile acids, thereby reducing total serum bile acid levels and relieving symptoms such as itching caused by cholestasis from the source. Studies have shown that many patients with PFIC experienced significant decreases in serum bile acid levels and significant improvements in skin itching scores after taking this drug.

In criticalPEDFIC-1 In phase III clinical trials, more than 90% of patients with PFIC treated with orvisibate experienced a decrease in bile acid levels after 24 weeks of treatment, and some of the patients achieved complete normalization. At the same time, these patients' nighttime itching symptoms were significantly reduced, their sleep quality was improved, and their daily living abilities were also improved. This shows that orvixibat can not only produce significant changes in laboratory indicators, but also actually improve patients' clinical symptoms and quality of life.

In terms of long-term efficacy, the PEDFIC-2 extension study results show that continuous administration of orvixibat for more than one year can still maintain good efficacy. Most patients' bile acid levels and pruritus scores continued to be maintained or further improved, and no new serious side effects were observed. This stability of long-term efficacy makes it an ideal treatment option for chronic cholestatic diseases. Researchers also found that some patients' liver function improved significantly while taking orvixibat, and even delayed the need for liver transplantation.

In general, orvixibat has shown good tolerability and long-lasting efficacy in actual clinical applications, and is particularly suitable for patients with PFIC that develops in childhood and progresses rapidly. Although the drug is not yet widely available in all countries, its remarkable efficacy has made it an important breakthrough in the treatment of cholestasis-related diseases. As further real-world studies are conducted, the scope of indications and long-term therapeutic benefits of this drug may be further expanded in the future.

Reference materials:https://www.drugs.com/